Last reviewed · How we verify
TIVA - Neostigmine 50
TIVA - Neostigmine 50 is a Cholinesterase inhibitor Small molecule drug developed by Pontificia Universidade Catolica de Sao Paulo. It is currently FDA-approved for Reversal of neuromuscular blockade, Myasthenia gravis, Postoperative ileus. Also known as: TIVA.
Neostigmine inhibits acetylcholinesterase, increasing acetylcholine levels at the neuromuscular junction to enhance muscle contraction.
Neostigmine inhibits acetylcholinesterase, increasing acetylcholine levels at the neuromuscular junction to enhance muscle contraction. Used for Reversal of neuromuscular blockade, Myasthenia gravis, Postoperative ileus.
At a glance
| Generic name | TIVA - Neostigmine 50 |
|---|---|
| Also known as | TIVA |
| Sponsor | Pontificia Universidade Catolica de Sao Paulo |
| Drug class | Cholinesterase inhibitor |
| Target | Acetylcholinesterase |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Neostigmine is a reversible cholinesterase inhibitor that prevents the breakdown of acetylcholine by acetylcholinesterase. This leads to accumulation of acetylcholine in the synaptic cleft, prolonging and enhancing neuromuscular transmission. It is used to reverse neuromuscular blockade and treat myasthenia gravis by improving muscle strength through increased acetylcholine availability.
Approved indications
- Reversal of neuromuscular blockade
- Myasthenia gravis
- Postoperative ileus
Common side effects
- Increased salivation
- Bronchospasm
- Bradycardia
- Muscle fasciculations
- Nausea and vomiting
Key clinical trials
- Total Knee Replacement TIVA With Robotic Arm Assisted (PHASE4)
- Three Different Doses of Neostigmine on the Reversal of Cisatracurium-induced Moderate Neuromuscular Blockade (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TIVA - Neostigmine 50 CI brief — competitive landscape report
- TIVA - Neostigmine 50 updates RSS · CI watch RSS
- Pontificia Universidade Catolica de Sao Paulo portfolio CI
Frequently asked questions about TIVA - Neostigmine 50
What is TIVA - Neostigmine 50?
How does TIVA - Neostigmine 50 work?
What is TIVA - Neostigmine 50 used for?
Who makes TIVA - Neostigmine 50?
Is TIVA - Neostigmine 50 also known as anything else?
What drug class is TIVA - Neostigmine 50 in?
What development phase is TIVA - Neostigmine 50 in?
What are the side effects of TIVA - Neostigmine 50?
What does TIVA - Neostigmine 50 target?
Related
- Drug class: All Cholinesterase inhibitor drugs
- Target: All drugs targeting Acetylcholinesterase
- Manufacturer: Pontificia Universidade Catolica de Sao Paulo — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Reversal of neuromuscular blockade
- Indication: Drugs for Myasthenia gravis
- Indication: Drugs for Postoperative ileus
- Also known as: TIVA